Last reviewed · How we verify

Scios, Inc. — Portfolio Competitive Intelligence Brief

Scios, Inc. pipeline: 1 marketed, 0 filed, 2 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 2 Phase 3 2 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
nesiritide, furosemide nesiritide, furosemide marketed Natriuretic peptide analog and loop diuretic combination Natriuretic peptide receptor-A (NPR-A) and Na-K-2Cl cotransporter Cardiovascular
usual long term cardiac medications usual long term cardiac medications phase 3
Natrecor (nesiritide) Natrecor (nesiritide) phase 3 Natriuretic peptide Natriuretic peptide receptor-A (NPR-A) Cardiovascular

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. LI ZHAO · 1 shared drug class
  2. M.D. Anderson Cancer Center · 1 shared drug class
  3. Nara Medical University · 1 shared drug class
  4. VA Office of Research and Development · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Scios, Inc.:

Cite this brief

Drug Landscape (2026). Scios, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/scios-inc. Accessed 2026-05-13.

Related